This paper describes multidisciplinary treatment incorporating neoadjuvant chemotherapy for head and neck cancer, especially focusing on maxillary sinus carcinoma (MSC) and nasopharyngeal carcinoma (NPC). For MSC, neoadjuvant chemotherapy included CDDP+PEP, ADR or THP-ADR+CDDP+PEP and CDDP+5-FU. The 5-year survival rate was 55% in 28 patients treated with this therapy and this group had a higher preservation rate of maxillo-facial functions and structures, compared with other treatments. However, the survival rate for T4 cases was very poor, so other therapeutic approaches are required. For NPC, neoadjuvant chemotherapy included CDDP+PEP, ADR+CDDP+PEP and ADR+CPA+PEP. The 5-year survival rate was 44% in 21 patients treated with this therapy, which was higher than that in patients who received other treatments to date. However, the frequency of distant metastasis did not always decrease in this group.